Superadditive cytostatic effects after combined administration of vincristine, bleomycin and methotrexate to Yoshida sarcoma.
Vincristine, bleomycin and methotrexate are three cytostatic drugs which are particularly effective in epidermoid carcinoma of the head and neck region. As their dose-limiting side effects differ from one another, it appeared reasonable to combine them. To examine in vitro whether this combination increases cytostatic activity, the three drugs were administered to Yoshida sarcoma. It could be demonstrated that the growth inhibition activity and the cell disturbance activity were much higher with combination therapy than with single drug therapy. From this, it follows that beneficial results in the treatment of head and neck carcinomas can be expected.
D000818:Animals; D001761:Bleomycin / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects*; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D006801:Humans; D066298:In Vitro Techniques; D008727:Methotrexate / Q000494:pharmacology*; D051379:Mice; D008815:Mice, Inbred Strains; D012517:Sarcoma, Yoshida / Q000188:drug therapy*; D014750:Vincristine / Q000494:pharmacology*
D001761:Bleomycin; D014750:Vincristine; D008727:Methotrexate